Long-Term Cardiomyopathy Risk Varies by Chemo Agent
Decreased risk seen for daunorubicin versus doxorubicin among survivors of childhood cancer
February 2019 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for February 2019. This roundup includes the latest...
February 2019 Briefing – Pain Management
Here are what the editors at HealthDay consider to be the most important developments in Pain Management for February 2019. This roundup includes the...
February 2019 Briefing – Geriatrics
Here are what the editors at HealthDay consider to be the most important developments in Geriatrics for February 2019. This roundup includes the latest...
February 2019 Briefing – Cosmetic Surgery
Here are what the editors at HealthDay consider to be the most important developments in Cosmetic Surgery for February 2019. This roundup includes the...
February 2019 Briefing – Anesthesiology
Here are what the editors at HealthDay consider to be the most important developments in Anesthesiology for February 2019. This roundup includes the latest...
February 2019 Briefing – Radiology
Here are what the editors at HealthDay consider to be the most important developments in Radiology for February 2019. This roundup includes the latest...
February 2019 Briefing – Pathology
Here are what the editors at HealthDay consider to be the most important developments in Pathology for February 2019. This roundup includes the latest...
February 2019 Briefing – Nephrology
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for February 2019. This roundup includes the latest...
February 2019 Briefing – Otolaryngology
Here are what the editors at HealthDay consider to be the most important developments in Otolaryngology for February 2019. This roundup includes the latest...
